Charles Robb Flynn

Has grant

Associate Professor

Vanderbilt University Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Gut-microbiota-related mechanisms that impact colorectal cancer risk after bariatric surgery

Open Date: 2023-09-01

Close Date: 2028-08-01

Articles (21)

Importance The association of bariatric surgery and newer glucagon-like peptide-1 receptor agonists (GLP-1RAs; semaglutide and tirzepatide) with body composition still lack evidence from clinical settings. Objective To examine temporal changes in fat-free mass (FFM), fat mass (FM), and FFM to FM ratio after bariatric surgery or GLP-1RA treatment over 24 months. Design, Setting, and Participants This retrospective cohort study used electronic health records from Vanderbilt University Medical Center of 1257 patients aged 18 to 65 years who underwent first-time bariatric surgery from November 21, 2017, to July 21, 2022, without GLP-1RA treatment from 1 year before to 2 years after surgery, and 1809 nonsurgical patients who started semaglutide or tirzepatide between November 12, 2018, and December 6, 2023, with 2 or more prescriptions or 5% or more weight loss. All patients had 2 or more bioelectrical impedance analysis measures and no history of end-stage kidney disease or congestive heart failure. Exposures Bariatric surgery or GLP-1RA (semaglutide or tirzepatide) treatment. Main Outcomes and Measures Relative changes in FFM, FM, and FFM to FM ratio over 24 months, controlling for age, sex, race, baseline body mass index (BMI), diabetes history, treatment year, time (restricted cubic splines), and time spline-by-treatment interaction. Results The study comprised 3066 patients: 1257 in the surgery group (mean [SD] age, 43.4 [10.3] years; mean [SD] baseline BMI, 46.8 [7.1]; 1033 women [82.2%]) and 1809 in the GLP-1RA group (mean [SD] age, 45.4 [11.3] years; mean [SD] baseline BMI, 41.0 [7.9]; 1457 women [80.5%]). Adjusted mean relative FM reductions in the surgery group were 42.4% (95% CI, 41.5%-43.2%) at 6 months, 49.7% (95% CI, 48.8%-50.6%) at 12 months, and 49.7% (95% CI, 47.8%-51.5%) at 24 months; reductions in the GLP-1RA group were 10.3% (95% CI, 9.5%-11.0%) at 6 months, 17.3% (95% CI, 16.5%-18.1%) at 12 months, and 18.0% (95% CI, 16.4%-19.7%) at 12 months. Adjusted mean relative FFM reductions in the surgery group were 7.8% (95% CI, 7.2%-8.4%) at 6 months, 10.6% (95% CI, 10.0%-11.2%) at 12 months, and 11.7% (95% CI, 10.4%-12.9%) at 24 months; reductions in the GLP-1RA group were 1.8% (95% CI, 1.3%-2.4%) at 6 months, 3.0% (95% CI, 2.4%-3.5%) at 12 months, and 3.3% (95% CI, 2.1%-4.4%) at 24 months. FFM to FM ratios increased significantly in both groups, with surgical patients maintaining a higher ratio throughout: the FFM to FM ratios in the surgery group were 1.8 (95% CI, 1.8-1.8) at 6 months, 2.1 (95% CI, 2.1-2.1) at 12 months, and 2.0 (95% CI, 2.0-2.1) at 24 months; the FFM to FM ratios in the GLP-1RA group were 1.4 (95% CI, 1.4-1.4) at 6 months, 1.5 (95% CI, 1.4-1.5) at 12 months, and 1.5 (95% CI, 1.5-1.6) at 24 months. Similar trends were observed in stratified analyses by sex, race, baseline BMI, baseline diabetes status, and GLP-1RA treatment duration, although men showed better FFM preservation than women, especially after GLP-1RA treatment. Conclusions and Relevance In this single-center cohort study, both bariatric surgery and semaglutide or tirzepatide treatment were associated with substantial FM loss, moderate FFM loss, and improved FFM to FM ratio. These findings provide evidence to guide interventions aimed at preserving FFM while promoting fat loss.

Year:

2026

Year:

2025

Background We applied the novel Predicting Risk of Cardiovascular Disease EVENTs equations to evaluate cardiovascular–kidney–metabolic (CKM) health and estimated cardiovascular disease (CVD) risk after bariatric surgery. Methods Among 7804 patients (aged 20–79 years) undergoing bariatric surgery at Vanderbilt University Medical Center during 1999 to 2022, CVD risk factors from before surgery to 2 years after surgery were extracted from electronic health records. The 10‐ and 30‐year risks of total CVD, atherosclerotic CVD, coronary heart disease, stroke, and heart failure (HF) were estimated for patients without CVD history at each time point (n=124–2910), using the social deprivation index–enhanced Predicting Risk of Cardiovascular Disease EVENTs equations. Paired t tests or McNemar tests were used to compare pre‐ with postsurgery CKM health and CVD risk. Two‐sample t tests were used to compare CVD risk reduction between patient subgroups. Results CKM health was significantly improved after surgery with lower systolic blood pressure, non–high‐density lipoprotein cholesterol, and diabetes prevalence, and higher high‐density lipoprotein and estimated glomerular filtration rate. The 10‐year risks of total CVD and its subtypes decreased by 21.7% to 56.3% at 1 year after surgery and by 14.6% to 46.5% at 2 years after surgery, with the largest reduction observed for HF. Younger age, White race, >30% weight loss, and diabetes history were associated with greater HF risk reductions. Similar results were found for the 30‐year CVD risk estimates. Conclusions Bariatric surgery significantly improves CKM health and reduces estimated CVD risk, particularly HF, by 47% to 56% within 1 to 2 years after surgery. HF risk reduction may vary by patient's demographics, weight loss, and disease history, which warrants further research.

Year:

2025

Year:

2025

Year:

2025

Metabolic homeostasis requires engagement of catabolic and anabolic pathways consuming nutrients that generate and consume energy and biomass. Our current understanding of cell homeostasis and metabolism, including how cells utilize nutrients, comes largely from tissue and cell models analyzed after fractionation, and that fail to reveal the spatial characteristics of cell metabolism, and how these aspects relate to the location of cells and organelles within tissue microenvironments. Here we show the application of multi-scale microscopy, machine learning-based image segmentation, and spatial analysis tools to quantitatively map the fate of nutrient-derived 13 C atoms across spatiotemporal scales. This approach reveals the cellular and organellar features underlying the spatial pattern of glucose 13 C flux in hepatocytes in situ, including the timeline of mitochondria-ER contact dynamics in response to changes in blood glucose levels, and the discovery of the ultrastructural relationship between glycogenesis and lipid droplets.

Year:

2025

Frailty, often linked to sarcopenia, involves reduced muscle strength and mass. While sarcopenia has multiple causes, impaired muscle protein synthesis may contribute. Leucine and resistance training (RT) are anabolic stimuli, but the long-term effects of leucine combined with RT in pre/frail older women remain unclear. This double-blind, placebo-controlled study aimed to assess their impact on muscle anabolism and characteristics in women consuming adequate protein. Pre/frail elderly women ( n = 19, 77.5 ± 1.3 y, BMI: 25.1 ± 0.9 kg/m 2 ), underwent 12 weeks of RT with protein-optimized diet (1.2 g ⋅ kg BW −1 ⋅ d −1 ) and were randomized to 7.5 g/d of leucine (Leu) or placebo 5.1 g/d alanine (Ala). The primary outcome was myofibrillar fractional synthesis rate (MyoFSR) in the postabsorptive and postprandial states. Secondary outcomes are changes in protein content and expression, 1-repetition maximum, body composition (DXA), and myofiber profiles were investigated. Overall MyoFSR increased by 47%, with a concomitant increase in type 1 and 2a myofiber cross sectional area (CSA) (16% and 28%, respectively), and total lean mass (2%). Total AKT, S6, and AMPKα levels were unchanged. However, AKT and S6 phosphorylation increased postprandially before RT, with no change following RT. The number of Frailty Criteria was reduced by 64%, with improvements in physical function and strength. Leucine had no added anabolic benefit. RT with optimal protein intake significantly improved the Frailty Phenotype and increased basal MyoFSR along with type 1 and 2a myofiber CSA and total lean mass, with no added benefit of leucine supplementation.

Year:

2025

Background: Products of lipid peroxidation include a number of reactive lipid aldehydes including reactive dicarbonyl electrophiles (DEs) and contribute to disease processes. DEs play a significant role in the development and progression of metabolic-associated steatotic liver disease (MASLD) by contributing to oxidative stress, inflammation, protein dysfunction, and mitochondrial impairment. Reducing DE stress may be a potential strategy for managing MASLD. We hypothesized that the DE scavenger 2-hydroxybenzylamine (2-HOBA) would reduce liver injury by reducing liver protein adduct formation by DE in mouse models of MASLD. Methods: Protein adducts were measured in human livers by immunohistochemistry and immunoblot. The effects of 2-HOBA were assessed in two different mouse models of MASLD. Results: Isolevuglandin (IsoLG) protein adducts were increased in MASH-staged human livers relative to histologically normal controls. Diet-Induced Animal Model of Nonalcoholic Fatty Liver Disease (DIAMOND) mice treated with 2-HOBA exhibited significantly lower fibrosis scores (* p = 0.012) and reduced liver transaminases (AST, p = 0.03) and ALT, p = 0.012) by over 40%. In STAM (Stelic Animal Model) mice, 2-HOBA improved NAFLD activity scores (p = 0.03, NAS), hyperglycemia, and inflammatory cytokines and reduced serum F2-isoprostanes (IsoPs) by 30%, p = 0.05. These improvements were absent mRNA changes in hepatic antioxidant enzymes (Cat, Gpx1, or Sod2) or ROS-generating proteins (p22PHOX, p47PHOX, NOX4 or COX1). Conclusions: DE scavenging with 2-HOBA may be a promising therapeutic strategy for managing MASLD. While findings are currently limited to male mice, a nutraceutical that reduces liver fibrosis could significantly improve the management of MASH by offering a non-invasive treatment option to potentially slow or reverse liver scarring, delay progression to cirrhosis, and improve patient outcomes, while also providing a potential treatment option for patients who may not be suitable for other interventions like liver transplantation.

Year:

2025

Objective Clinical studies struggle to locate the right patients, in part because many remain undiagnosed or lack relevant labels. We develop and prospectively test a physiology-based patient representation (‘Bioprofile’) to evaluate whether it can reduce the number of individuals who must be screened and enable more precise targeting of candidates for steatotic liver disease studies. Materials and Methods We trained Bioprofile patient representations from routinely collected health data and fine-tuned against multiple endpoints. Bioprofiles were trained using 1 million subjects from the UK Biobank and other cohorts. The trained model was applied to 45,484 research subjects at Vanderbilt University Medical Center. Based on Bioprofile nominations, 31 subjects were recruited for a prospective validation study. The primary outcome measure was proton density fat fraction (PDFF), an imaging-based metric of steatosis severity. Results Bioprofile models achieved a Spearman coefficient of 0.65 against PDFF, outperforming existing foundation models (ρ = 0.361) and clinical risk scores (ρ = 0.522-0.542) in retrospective validation. Simulations found that Bioprofiles required half as many subjects needed to screen compared to existing methods depending on task. Bioprofiles were further validated against 3 global cohort studies. Bioprofile predictions aligned strongly with prospective study data (ρ = 0.740). Discussion and Conclusion AI-based profiling of patient physiology can reveal individuals who have subclinical signatures of disease. If implemented widely, this approach can identify unknown human subjects, reduce screening failures, and improve trial quality. Bioprofiles may have additional utility in decision support applications in precision medicine and AI-augmented healthcare.

Year:

2025

The role of the gut‐to‐brain axis in the regulation of nutrient sensing has been studied extensively for decades. Research has mainly centered on vagal afferent and efferent neurotransmission along the gastrointestinal tract, followed by the integration of luminal information in the nodose ganglia and transmission to vagal integral sites in the brain. The physiological and cellular mechanisms of nutrient sensing by enterocytes and enteroendocrine cells have been well established; however, the roles of the enteric nervous system (ENS) remain elusive. Recent advances in targeting specific neuronal subpopulations and imaging techniques unravel the plausible roles of the ENS in nutrient sensing. In this review, we highlight physiological, cellular, and molecular insights that direct toward direct and indirect roles of the ENS in luminal nutrient sensing and vagal neurotransmission along the gut–brain axis and discuss functional maladaptations observed during metabolic insults, as observed during obesity and associated comorbidities, including type 2 diabetes.

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (26)

Ruben Martinez Barricarte

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Raymond Harris

Professor , Director of Research and Associate Program Director, Division of Nephrology

Vanderbilt University Medical Center

UNITED STATES
View details

Jason Samuels

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Craig R. Brooks

Associate Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Matthew Spann

Division Chief, General Surgery

Vanderbilt University Medical Center

UNITED STATES
View details

Danxia Yu

Vanderbilt University Medical Center

UNITED STATES
View details

Simon Vandekar

Associate Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Xiao‐Ou Shu

Vanderbilt University Medical Center

UNITED STATES
View details

You Chen

Vanderbilt University Medical Center

UNITED STATES
View details

Sabah Noori Hussain

Professor

McGill University

CANADA
View details

Marta Garcia-Contreras

MGH Institute of Health Professions

UNITED STATES
View details

jonathan brown

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Brandon Williams

Vanderbilt University Medical Center

UNITED STATES
View details

christianne roumie

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Edmond Rings

Prof. dr

Erasmus MC

NETHERLANDS
View details

Mariana Byndloss

Associate Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Kaidi Kang

Assistant Professor

Wake Forest Baptist Medical Center

UNITED STATES
View details

Quinn Wells

Associate Professor of Medicine

Vanderbilt University Medical Center

UNITED STATES
View details

Manuel Chiusa

Res. Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Wayne English

Vanderbilt University Medical Center

UNITED STATES
View details

Eric Gamazon

University of Chicago

UNITED STATES
View details

Jeremy Goettel

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Kristopher Burkewitz

Vanderbilt University

UNITED STATES
View details

Vance Albaugh

Assistant Professor of Metabolic Surgery

Pennington Biomedical Research Center

UNITED STATES
View details

Gitanjali Srivastava

Vanderbilt University School of Medicine

UNITED STATES
View details

Jeffrey Spraggins

Director

Vanderbilt University Medical Center

UNITED STATES
View details